Full-time researcher, Shenzhen Samii Medical Center

Postdoctor of Biomedical Sciences, The First Affiliated Hospital of Shenzhen University

PhD in Biomedical Engineering, Chongqing University

Main Research Field
(1) Anti-tumor function of natural killer cells

(2) Novel CAR-NK cells for immunotherapy

Representative Research Achievements

1. The project focuses on NK cell conditional knockout mouse and assesses the relevance of BMP signal pathway to anti-tumor function of NK cells. Moreover, this project enhances anti-tumor function of human NK cells by overexpressing BMP protein, which will open a new way to improve tumor immunotherapy.

2.NK cells are found in peripheral blood (PB) and umbilical cord blood (UCB), and can also be derived from stem cell sources, ranging from hematopoietic stem cells (HSCs) to human induced pluripotent stem cells (hiPSCs). The clinical scale expansion of NK cells enables the production of sufficient cells for immunotherapy. Our goal is to explore a strategy to obtain clinical-scale “of-the-shelf” CAR-NK cells derived from HSCs or hiPSCs.

Representative Publications

1. Ahmet Yilmaz,Hanwei cui#, Michael Caligiuri, Jianhua Yu*. Chimeric Antigen Receptor- Engineered Natural Killer Cells for Cancer Immunotherapy. J Hematol Oncol. 2020 Dec 7;13(1):168. (IF: 17.388)

2. Chaoliang Wei, Rui Xiao#, Liang Chen#,Hanwei Cui#, Yu Zhou, Yuanchao Xue, Jing Hu, Bing, Zhou, Taiki Tsutsui, Jinsong Qiu, Hairi Li, Liling Tang, Xiang-Dong Fu*. RBFox2 Binds Nascent RNA to Globally Regulate Polycomb Complex 2 Targeting in Mammalian Genomes. Mol Cell. 2016 Jun 16;62(6):982. (IF: 17.970)